• Most Popular
  • Most Shared

UPDATE 1-Medtronic to study stent in erectile dysfunction

Tue Oct 13, 2009 3:40pm EDT

Stocks

   

CHICAGO, Oct 13 (Reuters) - Medical device maker Medtronic Inc (MDT.N) on Tuesday said it has begun a feasibility study for a treatment for erectile dysfunction that uses a specially designed drug-eluting stent.

Stocks  |  Healthcare

The study, called Zen, is expected to enroll 50 subjects at up to 10 U.S. medical centers over the next year.

"The link between erectile dysfunction and coronary artery disease has been well established. Based on this evidence, we are investigating the use of stents in pelvic arteries to determine whether it may provide a new treatment approach and enable better response to drug therapies," Dr. Jason Rogers, director of interventional cardiology at UC Davis Medical Center in Sacramento and a lead investigator for the study, said in a statement.

The study is intended for men who have not responded well to PDE5 inhibitors such as Viagra, Cialis and Levitra.

The study will evaluate the safety and improved erectile function of pelvic artery stenting. Results are expected in 2011. (Reporting by Susan Kelly; Editing Bernard Orr)



More from Reuters

Photo

Euro zone holds intensive talks about Greek rescue

BERLIN/ATHENS (Reuters) - Euro zone countries were holding intensive talks on Wednesday about a possible financial rescue for debt-stricken Greece as civil servants staged the first major strike against Athens' crisis-driven austerity plan. | Video

 A protester marches next to a banner during an anti-government rally in Athens February 10, 2010. REUTERS/John Kolesidis
Analysis:

Will IMF step in on Greece?

Europe is loathe to turn to the International Monetary Fund to help bail out Greece but it may have little choice.  Full Article 

A worker drives a Toyota Motor Corp's newly assembled Prius hybrid vehicle onto a trailer near the company's plant in Toyota, central Japan February 9, 2010.REUTERS/Yuriko Nakao
Reuters Breakingviews:

Toyota's troubles in overdrive

The cost of Toyota's recall nightmare is nothing compared to the price of fixing its battered reputation.  Commentary